N@N

Daniel Busby Downgraded (VRCA) to Hold and Decreased Target to $4 on, May 25th, 2022

Daniel Busby of RBC Capital, Downgraded "Verrica Pharmaceuticals Inc." (VRCA) to Hold and Decreased Target from $16 to $4 on, May 25th, 2022.

Daniel has made no other calls on VRCA in the last 4 months.

There are 2 other peers that have a rating on VRCA. Out of the 2 peers that are also analyzing VRCA, 0 agree with Daniel's Rating of Hold.

These are the ratings of the 2 analyists that currently disagree with Daniel

---

• Kemp Dolliver of "Brookline Capital" Initiated at Strong Buy and Held Target at $20 on, Thursday, March 10th, 2022
• Serge Belanger of "Needham" Maintained at Strong Buy with Decreased Target to $18 on, Thursday, March 3rd, 2022